Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥1 to <7 Years With NF1-related Symptomatic, Inoperable PN
Clinical trial NCT05309668 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05309668
- Sponsor
- AstraZeneca
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-01-21
- Primary completion
- 2027-11-30
- Enrollment
- 36
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.